- Conditions
- Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Interventions
- High Dose Rate Monotherapy
- Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
Clinical trials in San Francisco, California
This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in San Francisco
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Postoperative Delirium, Postoperative Pain, Spinal Fusion
- Interventions
- Lidocaine IV, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
- Interventions
- Divarasib, Sotorasib, Adagrasib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Healthy Volunteer, Older Adults (65-85 Years)
- Interventions
- Psilocybin (Usona Institute)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
- Conditions
- Lupus Nephritis
- Interventions
- VIB4920, Placebo for VIB4920
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Multiple Myeloma, Plasma Cell Myeloma
- Interventions
- Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI), Fludeoxyglucose F-18
- Drug · Procedure · Other
- Lead sponsor
- Robert Flavell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Liver Transplant
- Interventions
- CMV-MVA Triplex, Placebo for CMV-MVA Triplex
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • La Jolla, California • Redwood City, California + 15 more
- Conditions
- Aortic Stenosis
- Interventions
- ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System, ACURATE Prime™ Transfemoral TAVR System XL
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,948 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
- Conditions
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
- Interventions
- Magnetocardiography
- Device
- Lead sponsor
- SB Technology, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer, Thoracic Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer
- Interventions
- Blood Specimen Collection, Stool Specimen Collection, Quality of Life (QOL) Questionnaires
- Procedure · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib
- Drug
- Lead sponsor
- Olema Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
- Interventions
- Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
- Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 482
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more